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Abstract
The treatment of opportunistic fungal infections is often difficult as the number of
available antifungal agents is limited. Nowadays, there is increasing interest in the
investigation of the antifungal activity of nonantifungal drugs, and in the
development of efficient antifungal combination therapy. In this study, the in vitro
interactions of the effects of various statins (lovastatin, simvastatin, fluvastatin,
atorvastatin (ATO), rosuvastatin (ROS) and pravastatin) and various azole
antifungals [miconazole, ketoconazole, itraconazole and fluconazole (FLU)]
against different opportunistic pathogenic fungi were investigated using a standard
chequerboard broth microdilution method. When the investigated strains were
sensitive to both compounds of the combination, additive interactions were
frequently noticed. Synergistic interactions were observed in many cases when a
strain was sensitive only to the azole compound (as in certain combinations with
ATO or ROS) or the statin compound (as in certain combinations with FLU). In
many combinations with an additive effect, the concentrations of drugs needed for
total growth inhibition could be decreased by several dilution steps. Similar
interactions were observed when the variability of the within-species sensitivities
to some selected drug combinations was investigated.
Introduction
The number of immunocompromised individuals with an
enhanced susceptibility to opportunistic fungal infections
has increased significantly in recent decades (Singh, 2001).
These mycoses are predominantly caused by Candida and
Aspergillus species (Walsh & Groll, 1999), but the incidence
of infections due to zygomycetous fungi has also risen
(Kauffman, 2004; Chayakulkeeree et al., 2006). As the
treatment of these fungal infections is frequently hampered
by the lack of an efficient antifungal agent, there is increas-
ing interest in the application of combination antifungal
therapy. Coadministration of two or three antifungal com-
pounds may improve the efficacy of the treatment, and
extends the spectrum of activity; furthermore, resistance
also may be avoided and toxicity reduced using lower
concentrations of the chemotherapeutic agents (Nosanchuk,
2006). As a result, a number of studies have focused on the
antifungal activity of nonantifungal drugs, and on the
development of efficient antifungal combination therapy
involving such compounds (Afeltra & Verweij, 2003;
Galgo´czy et al., 2009a).
Statins are used to reduce the cholesterol level in the
blood. They are competitive inhibitors of 3-hydroxy-3-
methylglutaryl-coenzyme A reductase, which catalyzes a
rate-limiting step in the acetate–mevalonate pathway of the
terpenoid biosynthesis (Liao & Laufs, 2005). Statins were
originally identified as secondary metabolites of fungi, and
various natural, chemically modified and synthetic com-
pounds are now available commercially, including lovastatin
(LOV), pravastatin (PRA), simvastatin (SIM), fluvastatin
(FLV), atorvastatin (ATO) and, most recently, rosuvastatin
(ROS) and pitavastatin (Schachter, 2005).
Statins are currently used for hyperlipidemia control
and protection from cardiovascular events, but they have
other pleiotropic properties, including anti-inflammatory,
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immunomodulatory and antioxidant effects (Liao & Laufs,
2005). In addition, there is increasing evidence for the
potential use of statins in preventing and treating infec-
tions (Falagas et al., 2008; Galgo´czy et al., 2009b), as they
attenuate the pathogenicity of microorganisms, modulat-
ing the signaling and other regulatory pathways involved in
controlling infection (Sun & Singh, 2009). Recent studies
have revealed their direct antimicrobial effect as well;
statins exert substantial growth-inhibitory effects on
pathogenic bacteria and fungi. The inhibitory effect of
LOV has been investigated in detail. LOV induced apopto-
sis-like cell death in Mucor racemosus (Roze & Linz, 1998)
and inhibited the growth of different Rhizomucor species
(Luka´cs et al., 2004). The fungistatic effect of LOV has been
demonstrated in Candida albicans (Gyetvai et al., 2006),
and the antifungal activities of SIM and ATO have been
observed against Aspergillus fumigatus and various Candi-
da species (Macreadie et al., 2006). The growth-inhibitory
effect of statins is probably based on their negative influ-
ence on membrane fluidity (Gyetvai et al., 2006). They also
indirectly affect cell signaling (Cordle et al., 2005), prolif-
eration and differentiation through inhibition of the
synthesis of important terpenoids (Miida et al., 2004).
Because of the fungus-specific or immunomodulating
actions of statins, it has been hypothesized that the wide-
spread use of statins by patients with diabetes has led to
lower rates of zygomycoses in developed countries since the
1990s (Kontoyiannis, 2007).
Some published work has suggested the possibility of the
combined application of statins and different antimycotics
(Chin et al., 1997; Chamilos et al., 2006; Galgo´czy et al.,
2007; Natesan et al., 2008; Nyilasi et al., 2010). Azoles are
a class of antifungal drugs that target the fungal cell
membrane by inhibiting the cytochrome P450-dependent
14a-lanosterol demethylase, which catalyzes a critical step of
ergosterol biosynthesis. Imidazoles, such as miconazole
(MCZ) and ketoconazole (KET), are generally used topi-
cally, whereas triazoles, such as fluconazole (FLU), itra-
conazole (ITR) and voriconazole, are applied orally or
intravenously against systemic mycoses.
The aim of our study was to examine the inhibition of
fungal growth by pairs of drugs, in order to find effective
drug combinations. Each pair contained a statin (LOV,
SIM, FLV, ATO, ROS or PRA) and an azole compound
(MCZ, KET, ITR and FLU). The in vitro interactions of the
effects of these compounds against some opportunistic
pathogenic yeasts and filamentous fungi were examined
using a standard chequerboard broth microdilution meth-
od. Clinically important Candida (C. albicans and Candida
glabrata) and Aspergillus species (A. fumigatus and Asper-
gillus flavus) and Rhizopus oryzae, the most frequent
causative agent of zygomycoses (Ribes et al., 2000), were
included in the study.
Materials and methods
Strains
All fungal isolates were collected from clinical sources. The
A. fumigatus and A. flavus strains were isolated in Indian
hospitals, and the C. albicans and C. glabrata strains in
Hungarian hospitals. These strains were deposited in the
Szeged Microbial Collection (SZMC) at the University of
Szeged, Szeged, Hungary. Eleven C. albicans (ATCC 1001,
ATCC 10231, SZMC 1458, SZMC 1379, SZMC 1421, SZMC
1453, SZMC 1363, SZMC 1456, SZMC 1411, SZMC 1426,
SZMC 1423), six C. glabrata (CBS 138, ATCC 35590, SZMC
1362, SZMC 1374, SZMC 1370, SZMC 1386), six A.
fumigatus (SZMC 2486, SZMC 2394, SZMC 2397, SZMC
2399, SZMC 2406, SZMC 2422), six A. flavus (SZMC 2521,
SZMC 2431, SZMC 2395, SZMC 2425, SZMC 2427, SZMC
2429) and one R. oryzae (syn. Rhizopus arrhizus) (CBS
109939) isolates were investigated. Candida albicans ATCC
90028 and Paecilomyces variotii ATCC 36257 were used as
quality-control strains in the antifungal susceptibility and
chequerboard broth microdilution tests.
Antifungal agents
The statins used in this study were FLV (Lescol; Novartis),
LOV (Mevacor; Merck Sharp & Dohme), SIM (Vasilip;
Egis), ROS (Crestor; AstraZeneca), ATO (Atorvox; Richter),
which were of pharmaceutical grade, and PRA (Sigma-
Aldrich), which was provided as standard powder. The
azoles used were MCZ, KET, FLU and ITR, which were also
provided by the manufacturer (Sigma-Aldrich) as standard
powders. The statins were dissolved in methanol, with the
exception of PRA, which was dissolved in distilled water;
stock solutions were prepared to a concentration of
12.8mgmL1. LOV and SIM were activated freshly from
their lactone prodrug forms by hydrolysis in ethanolic
NaOH (15%v/v ethanol, 0.25%w/v NaOH) at 60 1C for 1 h
(Lorenz & Parks, 1990). Stock solutions of MCZ, KET and
ITR were made in dimethyl sulfoxide (Sigma-Aldrich) at
concentrations of 1.6 or 0.8mgmL1, while FLU was
dissolved in dimethylformamide (Reanal) at a concentration
of 6.4mgmL1.
Antifungal susceptibility testing
The in vitro antifungal activities of the various azoles and
statins were determined using a broth microdilution meth-
od, which was performed in accordance with Clinical and
Laboratory Standards Institute guidelines (NCCLS, 1997,
2002). Minimal inhibitory concentration (MIC) values were
determined in 96-well flat-bottomed microtitre plates
by measuring the OD of the fungal cultures. In all experi-
ments, the test medium was RPMI 1640 (Sigma-Aldrich)
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containing L-glutamine, but lacking sodium bicarbonate,
buffered to pH 7.0 with 0.165M MOPS (Sigma-Aldrich).
Yeast cell inocula were prepared from 1-day-old cultures,
and fungal spore suspensions from 7-day-old cultures grown
on potato dextrose agar slants. Yeast or spore suspensions
were diluted in RPMI 1640 to give a final inoculum of
5 103CFUmL1 for yeasts and 5 104 sporesmL1 for
filamentous fungi. Series of twofold dilutions were prepared
in RPMI 1640 and were mixed with equal amounts of cell or
sporangiospore suspensions in the microtitre plates. The final
concentrations for each statin in the wells was 0.25–
128mgmL1, and for MCZ, KET, ITR and FLU, 0.031–16,
0.031–16, 0.016–8, and 0.125–64mgmL1, respectively.
The microplates were incubated for 48 h at 35 1C, and the
OD was measured at 620 nm with a microtitre plate reader
(Jupiter HD; ASYS Hitech). Uninoculated medium was
used as the background for the spectrophotometric calibra-
tion; the growth control wells contained inoculum suspen-
sion in the drug-free medium. The solvent control wells
contained inoculum suspension in the drug-free solvent-
containing (1%) medium to prove that solvent had no
inhibitory effect on the investigated fungi at the applied
concentration. For calculation of the extent of inhibition,
the OD620 nm of the drug-free control cultures was set at
100% growth. The MICs for statins were the lowest con-
centration of drugs that produced an optically clear well,
while the MICs for azoles were the lowest concentration
of drugs that produced a prominent decrease in turbidity.
The quality-control strains were included every time an
isolate was tested. All experiments were repeated at least
three times.
Chequerboard broth microdilution method
For drug interaction studies, each statin was tested with each
azole by the chequerboard broth microdilution method,
using twofold dilutions of both drugs. The final concentra-
tions of the various statins in the rows were
0.391–25 mgmL1. The final concentrations of the azoles in
the wells, the inoculum preparation, the initial inoculum,
the controls and the conditions of the incubation were as
described above for antifungal susceptibility testing. The
interaction ratio (IR) between the antifungal agents was
calculated using the Abbott formula: IR = Io/Ie, where Io is
the observed percentage inhibition and Ie is the expected
percentage inhibition for a given interaction. Ie was calcu-
lated using the formula: Ie = x1y (xy/100), where x and y
are the percentage inhibitions observed for each compound
when applied alone. The IR reflects the nature of the
interaction between the antifungal compounds: if IR is
between 0.5 and 1.5, the interaction is considered additive,
an IR4 1.5 denotes synergism and an IRo 0.5 denotes
antagonism (Gisi, 1996).
Results
In vitro susceptibility testing
The 50%, 80% and 90% growth-inhibitory concentrations
(IC50, IC80 and IC90) of the various azoles against C. albicans
ATCC 90028, C. glabrata CBS 138, A. fumigatus SZMC 2486,
A. flavus SZMC 2521, R. oryzae CBS 109939 and P. variotii
ATCC 36257 were determined (Tables 1–4). Among the
azoles, ITR had the strongest inhibitory effect; it completely
blocked the growth of all tested isolates at low concentration
(o 1 mgmL1). MCZ and KET were equally effective, their
inhibitory concentrations ranging from 0.5 to 8 mgmL1 for
all tested strains. Conversely, FLU only inhibited the growth
of yeasts, and was ineffective against the filamentous fungi in
the administered concentrations. In the case of C. albicans,
ITR, KET and FLU showed the trailing effect, which means
that the growth inhibition was only 50–60% at low azole
concentrations (0.016mgmL1 for ITR, 0.031 mgmL1 for
KET and 0.25 mgmL1 for FLU), but this inhibitory effect
could not be enhanced further by the application of higher
drug concentrations, and complete blockage of growth
could not be achieved.
The MICs of the involved statins against the same six
fungal strains (Tables 1–4) have already been reported
(Nyilasi et al., 2010). Those results showed that FLV and
SIM exhibited potent antifungal activities and frequently a
higher activity than the other statins. The natural statins
(SIM and LOV) were inactive in their prodrug forms, but
their active metabolites obtained by hydrolysis of the lactone
ring manifested pronounced antifungal effects (Nyilasi et al.,
2010).
Interactions between azoles and statins
The in vitro interactions between the various azoles and
statins were also studied against the abovementioned six
fungal strains. We tested all investigated statins in combina-
tion with all investigated azoles, and in most cases, positive
interactions were observed between them. Antagonistic
interactions were not observed between any of the statins
and azole compounds. Tables 1–4 show the data for all tested
drug combinations. We could not display the results of all
azole–statin combinations because of the huge amount of
data. Thus, in Tables 1–4, only examples for concentrations
of the combined drugs causing total growth inhibition are
presented. The types of interaction, as well as IR values, are
also given.
Additive interactions were generally noticed when the
investigated strains were sensitive to both of the combined
compounds. Such effects were observed in yeasts when KET
and ITRwere combined with any of the statins (Tables 1 and 4).
In the case of C. albicans, sole application of ITR, KET and
FLU caused a trailing effect, but complete blockage of
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growth could be achieved with almost all azole–statin
combinations at very low concentrations. Moreover, syner-
gistic interaction was observed when ITR was combined
with ROS (IR= 1.79). In some cases, synergistic interactions
were observed when the investigated strain was sensitive to
both compounds. For example, FLU and FLV acted
Table 1. Effect of antifungal activity of KET combined with different statins
Isolate/statin [MIC alone (mg mL1)]
ICs of KET (mg mL1)w
MIC (mg mL1) of KET and MIC (mg mL1)
of the different statins in combination [effect, IR]zIC50 IC80 IC90
Candida albicans ATCC 90028 0.031 4 16 4 16
LOV [50–64] 0.03116.25 [A, 1.31], 1613.125 [A, 1.16]
SIM [8] 0.03111.563 [A, 1.44]
FLV [25] 0.03111.563 [A, 1.11], 0.06310.781 [A, 1.26], 810.391 [A, 1.32]
ROS [128] 0.031112.5 [A, 1.07], 0.2516.25 [A, 0.99], 813.125 [A, 1.25]
ATO [128] 0.031125 [A, 1.29], 0.063112.5 [A, 0.92], 1613.125 [A, 1.10]
PRA [4128] [I]‰
Candida glabrata CBS 138 0.063–0.125 0.25 0.5–2
LOV [128] 0.25125 [A, 1.49], 0.511.563 [A, 1.13]
SIM [16–32] 0.125125 [A, 0.80], 0.2513.125 [A, 0.73], 0.510.391 [A, 0.81]
FLV [64] 0.125125 [A, 1.0], 0.2510.781 [A, 0.95], 0.510.391 [A, 0.88]
ROS [128] 0.251 12.5 [A, 1.08], 0.513.125 [A, 1.22]
ATO [32] 0.1251 12.5 [A, 1.38], 0.2510.781 [A, 0.89]
PRA [4128] 0.513.125 [A, 0.73], 110.391 [A, 1.05]
Paecilomyces variotii ATCC 36257 0.125–0.25 0.5 1
LOV [64] 0.125150 [A, 0.73], 0.5125 [A, 0.59]
SIM [8] [I]‰
FLV [25] 0.063112.5 [A, 1.08], 0.516.25 [A, 0.64]
ROS [32] 0.513.125 [A, 1.05]
ATO [32] [I]‰
PRA [4128] [I]‰
Aspergillus fumigatus SZMC 2486 1–2 2–4 4–8
LOV [25] 0.513.125 [A, 0.78], 111.563 [A, 0.70]
SIM [6.25] 111.563 [A, 1.46], 410.391 [A, 0.73]
FLV [2] 0.511.563 [A, 0.81], 210.781 [A, 0.74]
ROS [128] 1125 [A, 1.36], 2112.5 [A, 1.09]
ATO [64] 1125 [S, 2.70], 410.781 [A, 1.16]
PRA [4128] [I]‰
Aspergillus flavus SZMC 2521 1–2 2 4
LOV [4128] 211.563 [A, 0.80]
SIM [4128] 216.25 [A, 1.15]
FLV [128] 0.5112.5 [S, 1.79], 113.125 [A, 1.35], 210.391 [A, 0.74]
ROS [4128] [I]‰
ATO [4128] 2125 [A, 1.23]
PRA [4128] 210.391 [A, 1.09]
Rhizopus oryzae CBS 109939 1–2 1–4 2–4
LOV [128] [I]‰
SIM [64] [I]‰
FLV [2–3.125] 0.2511.563 [A, 1.06], 0.510.781 [S, 1.65], 110.391 [S, 2.61]
ROS [4128] 0.25125 [A, 1.37], 1112.5 [S, 2.14]
ATO [32] 0.5112.5 [A, 1.22], 113.125 [A, 1.43], 210.391 [S, 3.05]
PRA [4128] [I]‰
The MICs of the statins are shown in parentheses.
wIC50, IC80 and IC90 values are the concentrations required for 50%, 80% and 90% growth inhibition.
zExamples of effective concentrations of the combined drugs causing total growth inhibition are presented; the first number indicates the concentration
of KET, and the second the concentration of the given statin. The type of the interaction (A, additive; S, synergistic; I, indifferent) and IR values are
presented in parentheses.
‰Interaction was considered indifferent if no difference in the inhibition rates was detected (i.e. the MIC or IC values of the drugs could not decreased by
their combined applications).
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synergistically against C. albicans (IR= 1.70), KET and SIM
against A. fumigatus (IR= 1.46), and ITR and FLV against
R. oryzae (IR= 2.24).
When the investigated strain was sensitive to only the
azole compound, but insensitive to the given statin (or the
statin inhibited its growth only in high concentrations), the
Table 2. Effect of antifungal activity of MCZ combined with different statins
Isolate/statin [MIC alone (mg mL1)]
ICs of MCZ (mg mL1)w
MIC (mg mL1) of MCZ and MIC (mg mL1)
of the different statins in combination [effect, IR]zIC50 IC80 IC90
Candida albicans ATCC 90028 0.063–0.125 2–4 8
LOV [50–64] 0.125112.5 [A, 0.88]
SIM [8] 0.03116.25 [A, 0.86], 0.06313.125 [S, 1.65], 0.12511.563 [A, 1.0]
FLV [25] 0.03111.563 [A, 1.17]
ROS [128] 0.125112.5 [S, 1.66], 0.516.25 [A, 1.45]
ATO [128] 0.25125 [S, 1.54], 1112.5 [A, 1.16]
PRA [4128] [I]‰
Candida glabrata CBS 138 0.063–0.125 0.125–0.25 0.5–2
LOV [128] 0.125150 [A, 1.13], 0.2513.125 [A, 1.11]
SIM [16–32] 0.125112.5 [A, 0.68], 0.2511.563 [A, 1.14], 0.510.391 [A, 0.80]
FLV [64] 0.125125 [A, 1.01], 0.2511.563 [A, 0.80]
ROS [128] 0.2516.25 [A, 0.94], 0.513.125 [A, 0.91], 111.563 [A, 0.94]
ATO [32] 0.063112.5 [A, 1.13], 0.12510.781 [A, 0.74]
PRA [4128] 0.513.125 [A, 1.02], 110.781 [A, 1.04]
Paecilomyces variotii ATCC 36257 0.25–0.5 4 8–16
LOV [64] 0.5150 [A, 0.53], 2125 [A, 0.53], 4112.5 [A, 0.57]
SIM [8] [I]‰
FLV [25] 1112.5 [A, 0.63], 816.25 [A, 0.59]
ROS [32] 8112.5 [A, 0.59]
ATO [32] 810.391 [A, 0.62]
PRA [4128] [I]‰
Aspergillus fumigatus SZMC 2486 1–2 2 4
LOV [25] 1112.5 [A, 0.72], 216.25 [A, 1.05]
SIM [6.25] 0.06311.563 [A, 1.07], 110.781 [A, 1.28], 210.391 [A, 0.86]
FLV [2] 0.511.563 [A, 0.82], 210.391 [A, 0.81]
ROS [128] 216.25 [A, 1.29]
ATO [64] 1125 [S, 2.12], 210.781 [A, 1.37]
PRA [4128] [I]‰
Aspergillus flavus SZMC 2521 1–2 2 4
LOV [4128] [I]‰
SIM [4128] 211.563 [A, 0.96]
FLV [128] 0.5125 [S, 2.43], 116.25 [S, 2.46], 210.781 [A, 0.85]
ROS [4128] [I]‰
ATO [4128] [I]‰
PRA [4128] 210.391 [A, 1.07]
Rhizopus oryzae CBS 109939 2–4 2–4 4
LOV [128] 2150 [A, 1.01]
SIM [64] 210.781 [A, 1.10]
FLV [2–3.125] 0.12513.125 [A, 1.28], 211.563 [A, 0.78]
ROS [4128] 2112.5 [A, 1.02]
ATO [32] [I]‰
PRA [4128] [I]‰
The MICs of the statins are shown in parentheses.
wIC50, IC80 and IC90 values are the concentrations required for 50%, 80% and 90% growth inhibition.
zExamples for effective concentrations of the combined drugs causing total growth inhibition are presented; the first number indicates the
concentration of MCZ, and the second the concentration of the given statin. The type of the interaction (A, additive; S, synergistic; I, indifferent) and
IR values are presented in parentheses.
‰Interaction was considered indifferent if no difference in the inhibition rates was detected (i.e. the MIC or IC values of the drugs could not decreased by
their combined applications).
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combined administration of azoles and statins decreased the
concentrations needed to achieve the complete blockage of
growth by several dilution steps. Such synergistic effects
were observed, for example, in the case of C. albicans, when
MCZ was combined with ROS (IR = 1.66) or LOV was
combined with FLU (IR = 25.2). The combination of KET
Table 3. Effect of antifungal activity of FLU combined with different statins
Isolate/statin [MIC alone (mg mL1)]
ICs of FLU (mg mL1)w
MIC (mg mL1) of FLU and MIC (mg mL1)
of the different statins in combination [effect, IR]zIC50 IC80 IC90
Candida albicans ATCC 90028 0.125–0.25 4–64 4 64
LOV [50–64] 0.125112.5 [S, 25.2], 0.2516.25 [S, 2.67], 0.513.125 [A, 1.32]
SIM [8] 0.12516.25 [A, 0.95], 0.2511.563 [A, 1.15]
FLV [25] 0.12516.25 [S, 1.70], 0.2511.563 [A, 1.0]
ROS [128] 16125 [A, 1.30], 64112.5 [A, 1.26]
ATO [128] 0.125112.5 [A, 1.25]
PRA [4128] [I]‰
Candida glabrata CBS 138 2–4 4–8 8–16
LOV [128] 0.25150 [A, 1.17], 4125 [S, 1.65]
SIM [16–32] 4125 [A, 0.99], 810.391 [A, 1.25]
FLV [64] 1125 [A, 1.12], 4112.5 [A, 0.96], 810.781 [A, 0.96]
ROS [128] 8125 [A, 1.12]
ATO [32] 1125 [S, 1.51], 416.25 [A, 0.81]
PRA [4128] [I]‰
Paecilomyces variotii ATCC 36257 4 64 4 64 4 64
LOV [64] 0.125150 [A, 1.09]
SIM [8] [I]‰
FLV [25] [I]‰
ROS [32] z
ATO [32] z
PRA [4128] z
Aspergillus fumigatus SZMC 2486 4 64 4 64 4 64
LOV [25] 1616.25 [S, 1.60]
SIM [6.25] 0.12513.125 [A, 1.20], 811.563 [S, 2.20]
FLV [2] 0.2511.563 [A, 0.79]
ROS [128] z
ATO [64] 8125 [S, 2.88]
PRA [4128] z
Aspergillus flavus SZMC 2521 4 64 4 64 4 64
LOV [4128] z
SIM [4128] z
FLV [128] z
ROS [4128] z
ATO [4128] z
PRA [4128] z
Rhizopus oryzae CBS 109939 4 64 4 64 4 64
LOV [128] 64150 [A, 0.96]
SIM [64] z
FLV [2–3.125] [I]‰
ROS [4128] z
ATO [32] z
PRA [4128] z
The MICs of the statins are shown in parentheses.
wIC50, IC80 and IC90 values are the concentrations required for 50%, 80% and 90% growth inhibition.
zExamples for effective concentrations of the combined drugs causing total growth inhibition are presented; the first number indicates the
concentration of FLU, and the second the concentration of the given statin. The type of the interaction (A, additive; S, synergistic; I, indifferent) and IR
values are presented in parentheses.
‰Interaction was considered indifferent if no difference in the inhibition rates was detected (i.e. the MIC or IC values of the drugs could not decreased by
their combined applications).
zComplete growth inhibition was not detected in the administered concentration range.
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and ATO also acted synergistically against R. oryzae
(IR= 3.05), while the combinations of MCZ and ATO
(IR= 2.12) and ITR and ATO (IR= 46.5) acted synergisti-
cally against A. fumigatus. Filamentous fungi were comple-
tely insensitive to FLU; however, FLU acted synergistically
against A. fumigatus in combination with LOV, SIM and
Table 4. Effect of antifungal activity of ITR combined with different statins
Isolate/statin [MIC alone (mg mL1)]
ICs of ITR (mg mL1)w
MIC (mg mL1) of ITR and MIC (mg mL1)
of the different statins in combination [effect, IR]zIC50 IC80 IC90
Candida albicans ATCC 90028 0.016 4 16 4 16
LOV [50–64] 0.031112.5 [A, 1.43]
SIM [8] 0.01610.781 [A, 1.05]
FLV [25] 0.03111.563 [A, 1.02]
ROS [128] 0.031125 [S, 1.79], 1112.5 [A, 1.46]
ATO [128] 0.031112.5 [A, 1.27]
PRA [4128] [I]‰
Candida glabrata CBS 138 0.063–0.125 0.25–0.5 0.5–1
LOV [128] 0.510.781 [A, 1.05]
SIM [16–32] 0.063125 [A, 0.90], 0.25112.5 [A, 0.71], 0.510.781 [A, 0.77]
FLV [64] 0.12516.25 [A, 0.95], 0.2511.563 [A, 0.82], 0.510.391 [A, 0.79]
ROS [128] 0.2516.25 [A, 1.08]
ATO [32] 0.063125 [A, 1.17], 0.125112.5 [A, 1.14], 0.2510.781 [A, 0.70]
PRA [4128] [I]‰
Paecilomyces variotii ATCC 36257 0.016–0.031 0.063–0.125 0.125–0.25
LOV [64] 0.031125 [A, 0.59], 0.125112.5 [A, 0.78]
SIM [8] [I]‰
FLV [25] 0.031112.5 [A, 0.88], 0.06316.25 [A, 0.86]
ROS [32] 0.06310.781 [A, 1.05]
ATO [32] 0.016112.5 [A, 0.72], 0.03110.781 [A, 0.68]
PRA [4128] [I]‰
Aspergillus fumigatus SZMC 2486 0.031–0.125 0.125–0.25 0.25–0.5
LOV [25] 0.125112.5 [A, 1.43], 0.2513.125 [A, 0.77]
SIM [6.25] 0.03110.781 [A, 0.67], 0.12510.391 [A, 0.67]
FLV [2] 0.03111.563 [A, 0.84], 0.06310.391 [A, 1.01]
ROS [128] 0.031125 [S, 2.81], 0.063112.5 [S, 1.68], 0.12510.391 [A, 0.90]
ATO [64] 0.016125 [S, 1.99], 0.06316.25 [S, 2.62], 0.12510.391 [S, 46.5]
PRA [4128] [I]‰
Aspergillus flavus SZMC 2521 0.125 0.125–0.25 0.25–0.5
LOV [4128] 0.25112.5 [A, 1.15]
SIM [4128] 0.2510.781 [A, 1.41]
FLV [128] 0.031112.5 [A, 1.23], 0.06316.25 [S, 1.56], 0.12510.391 [A, 0.92]
ROS [4128] 0.125112.5 [A, 1.38]
ATO [4128] 0.12513.125 [S, 1.65]
PRA [4128] [I]‰
Rhizopus oryzae CBS 109939 0.25–0.5 0.25–1 0.5–2
LOV [128] 110.781 [A, 1.25]
SIM [64] [I]‰
FLV [2–3.125] 0.03113.125 [A, 1.13], 0.12511.563 [S, 1.94], 0.2510.391 [S, 2.24]
ROS [4128] 0.063125 [A, 1.18], 0.25112.5 [A, 1.27], 0.513.125 [S, 2.15]
ATO [32] 0.016125 [A, 1.13], 0.12516.25 [A, 1.31], 0.2510.781 [S, 1.50]
PRA [4128] [I]‰
The MICs of the statins are shown in parentheses.
wIC50, IC80 and IC90 values are the concentrations required for 50%, 80% and 90% growth inhibition.
zExamples for effective concentrations of the combined drugs causing total growth inhibition are presented; the first number indicates the
concentration of ITR, and the second the concentration of the given statin. The type of the interaction (A, additive; S, synergistic; I, indifferent) and IR
values are presented in parentheses.
‰Interaction was considered indifferent if no difference in the inhibition rates was detected (i.e. the MIC or IC values of the drugs could not decreased by
their combined applications).
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ATO (IR= 1.60, 2.20 and 2.88, respectively). Aspergillus
flavus was sensitive to FLV only at high concentration
(128mgmL1), but acted synergistically in combination with
KET, MCZ and ITR (IR = 1.79, 2.46 and 1.56, respectively).
No complete inhibition of A. flavus was observed with any
FLU–statin combination. Although FLU and FLV acted
synergistically against this fungus (IR= 3.88), only 50%
growth inhibition could be achieved at the highest applied
concentrations (64 mgmL1 FLU combined with 25 mgmL1
FLV). The high values of IR appear when the combination of
drugs caused total growth inhibition at a certain concentra-
tion, but the compounds alone had no inhibitory effect at
that concentration.
Some experiments were carried out to acquire prelimin-
ary information concerning the variability of the sensitiv-
ities within species to these drugs and their combinations. A
summary of these results is presented in Table 5. Two of the
promising synergistic combinations, FLU–FLV and FLU–
LOV, were tested against 12 C. albicans isolates. All investi-
gated strains proved to be sensitive to the FLU–FLV combi-
nation; moreover, some clinical strains were more sensitive
than normal. Synergism was observed in the case of five
isolates; otherwise, additive effects were noted. At the same
time, C. albicans strains were diversely sensitive to the
FLU–LOV combination, which derived from their different
sensitivities to LOV. Some clinical strains were also more
sensitive than average, so synergistic interactions could be
achieved with low concentrations. FLU was efficient against
all isolates, and the interaction between the two drugs was
always positive (synergistic or additive effect). KET–FLV
interactions were synergistic against almost every A. flavus
isolate, but their sensitivities to FLV differed by one or two
dilution steps. The effects of MCZ–SIM combination
against C. glabrata and the KET–SIM and ITR–ATO combi-
nation against A. fumigatus were also similar to those
observed previously, but the sensitivities to the given azole
compound differed by one or two dilution steps between the
isolates. In general, these drugs proved to be more effective
against all tested strains in combination than alone; how-
ever, the sensitivities to the statin or the azole compound
sometimes varied in a narrow range among the isolates of a
species.
Discussion
The treatment of Candida infections is generally based on
azole therapy, whereas azoles and amphotericin B are
primarily used against filamentous fungi. Azoles inhibit the
fungal growth even at low concentrations; however, their
endpoint determination is of major importance, especially
for isolates exhibiting trailing growth. Azoles do not cause
cessation of growth soon after the exposure to the drug;
fungal growth begins to slow down after one doubling time
and is fully arrested only some time later (Rex et al., 1993).
Some turbidity may persist for all drug concentrations
tested and only partial inhibition of growth can be achieved,
which results in the phenomenon of the trailing endpoint.
So the endpoint for azoles has been defined as the point at
which there is prominent reduction in growth. This end-
point could also be referred to as 80% reduction in growth
relative to the growth control (IC80); however, for micro-
dilution testing 50% inhibition of growth (IC50) measured
by spectrophotometry best approximates the visual end-
point (Pfaller et al., 1995).
It is known that statins have antifungal effect, although it
is worth mentioning that they only inhibit the fungal growth
at relatively high concentrations, well above the maximum
achievable serum levels in humans (Kivisto¨ et al., 1998). In
the present study, we detected additive or synergistic inter-
actions between statins and azoles in many cases at concen-
trations clinically achievable in the human serum. Some
earlier publications also reported in vitro interaction studies
between certain statins and azoles (Chin et al., 1997; Nash
et al., 2002; Chamilos et al., 2006); however, in these studies,
only one or two statins combined with one or two other
antimycotics were involved, and systematic screening of the
efficient statin–azole combinations was not performed.
Chin et al. (1997) detected synergistic and additive effects
of FLV combined with FLU or ITR against different Candida
species and Cryptococcus neoformans; however, FLV was used
at a higher concentration than is clinically achievable
(4–8 mgmL1). Nash et al. (2002) investigated the in vitro
activity of FLU in combination with clinically relevant
concentrations of FLV and PRA (1 and 0.25mg L1, respec-
tively) against C. albicans, but did not observe any synergis-
tic effect. On the other hand, Chamilos et al. (2006)
demonstrated significant in vitro synergism between LOV
and voriconazole against several Zygomycetes when both
drugs were applied in the range of clinically achievable
concentrations.
The activities observed for certain azole–statin combina-
tions highlight the promise of these compounds as candi-
dates for the treatment of opportunistic human and animal
Table 5. Variability of the within species sensitivities against some
statin–azole combinations
Microorganisms
[no. of isolates] Combinations
Interactions
[no. of cases]
Candida albicans [12] LOV1FLU A [8], S [4]
FLV1FLU A [7], S [5]
Candida glabrata [6] SIM1MCZ A [5], S [1]
Aspergillus fumigatus [6] SIM1KET A [6]
ATO1ITR S [3], A [3]
Aspergillus flavus [6] FLV1KET S [5], A [1]
A, additive interaction; S, synergistic interaction.
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mycoses. However, the application of the azole–statin com-
binations is substantially limited because severe drug inter-
actions can arise when these drugs are coadministered. As
these agents are metabolized by the same cytochrome P450
enzyme in the liver (CYP3A4), azoles have an effect on the
pharmacokinetics of certain statins by reducing their meta-
bolic clearance (Kivisto¨ et al., 1998). The increased concen-
tration of the coadministered statins in the serum may cause
severe side effects in the patients, such as myositis and
rhabdomyolysis (Herman, 1999; Mazzu et al., 2000). This
limits their systemic administration, but the azole–statin
combinations may be applicable as topical therapy for
patients with oropharyngeal candidosis or other mucocuta-
neous infections. Furthermore, FLV and PRA have a lower
potential than other statins for metabolic drug–drug inter-
actions, as FLV is predominantly metabolized by the
CYP2C9 isoenzyme (Fischer et al., 1999), whereas PRA is
excreted by the renal mechanism and does not undergo
significant metabolism via the cytochrome P450 system
(Triscari et al., 1995). In our work, PRA alone proved to be
ineffective against the investigated isolates; but it decreased
the MICs of KET and MCZ fourfold in the cases of
C. glabrata. At the same time, FLV had a strong inhibitory
effect against all investigated fungi, and interacted synergis-
tically with the azoles in several cases.
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